Nov. 13, 2012
/PRNewswire/ -- PuraMed BioScience
, Inc,. (OTCQB: PMBS) announces that its homeopathic migraine formulation,
, has been recognized as an excellent first-line therapy in the treatment of acute migraine. The declaration was made in the online article
Advances in Drug Development for Acute Migraine
scheduled for publication in an upcoming printed issue of
, a medical journal evaluating drugs and drug therapies read by over 500,000 healthcare providers.
Ryan J. Cady
Candace L. Shade
Roger K. Cady, MD
, reviewed 11 drugs, which are considered advancements in acute migraine treatment. LipiGesic M was the only product described as
"an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options."
"With this '
excellent first-line therapy'
designation, consumers can be assured that headache experts have reviewed the clinical study evidence for LipiGesic M's efficacy and have determined that LipiGesic M is the first medication sufferers should take to relieve migraine pain and migraine associated symptoms," said
, president and CEO of PuraMed BioScience.
LipiGesic M is an over-the-counter, homeopathic formulation of feverfew and ginger delivered in a sublingual (under-the-tongue) gel for the acute treatment of migraine. Sublingual delivery preserves the effectiveness of the active ingredients since they are absorbed directly into the blood stream bypassing the digestive system where breakdown occurs.
"Migraine sufferers are looking for relief, but many current treatments produce severe and often debilitating side effects," said Mitchell. "Our non-drowsy formulation can relieve migraine headaches without medication hangover symptoms at a fourth of the cost of the top-selling prescription treatments. Inclusion in the article as the only over-the-counter product in the advancement of acute migraine treatment with the advantages of lower cost and little to no risk of medication overuse or rebound headaches is encouraging.